Beam Therapeutics (BEAM) EPS (Weighted Average and Diluted) (2019 - 2026)
Beam Therapeutics (BEAM) reported EPS (Weighted Average and Diluted) of -$0.91 for Q1 2026, up 26.02% year-over-year from -$0.72 in Q1 2025, and down 136.25% quarter-over-quarter from $2.51 in Q4 2025.
Beam Therapeutics (BEAM) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 8 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.91 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.91, up 26.02% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.5 (up 89.13% YoY), and the FY2025 annual result was -$0.81, up 82.31% from the prior year.
- EPS (Weighted Average and Diluted) eased to -$0.91 in Q1 2026 per BEAM's latest filing, from $2.51 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $2.51 in Q4 2025 and troughed at -$1.56 in Q3 2022.
- A 5-year average of -$0.72 and a median of -$1.09 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) tumbled 271.43% in 2022, then soared 453.7% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.54 in 2022, then soared by 453.7% to $1.91 in 2023, then plunged by 157.07% to -$1.09 in 2024, then surged by 330.28% to $2.51 in 2025, then tumbled by 136.25% to -$0.91 in 2026.
- Business Quant data shows BEAM's EPS (Weighted Average and Diluted) at -$0.91 in Q1 2026, $2.51 in Q4 2025, and -$1.1 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Beam Therapeutics | 3.53 Bn | 3.53 Bn | - | -0.91 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.91 |
| Dec 31, 2025 | 2.51 |
| Sep 30, 2025 | -1.10 |
| Jun 30, 2025 | -1.00 |
| Mar 31, 2025 | -1.23 |
| Dec 31, 2024 | -1.09 |
| Sep 30, 2024 | -1.17 |
| Jun 30, 2024 | -1.11 |
| Mar 31, 2024 | -1.21 |
| Dec 31, 2023 | 1.91 |
| Sep 30, 2023 | -1.22 |
| Jun 30, 2023 | -1.08 |
| Mar 31, 2023 | -1.33 |
| Dec 31, 2022 | -0.54 |
| Sep 30, 2022 | -1.56 |
| Jun 30, 2022 | -1.02 |
| Mar 31, 2022 | -1.01 |
| Dec 31, 2021 | -0.91 |
| Sep 30, 2021 | -0.42 |
| Jun 30, 2021 | -1.23 |